A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors.

Shivange G, Mondal T, Lyerly E, Bhatnagar S, Landen CN, Reddy S, Kim J, Doan B, Riddle P, Tushir-Singh J. A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors. Cell Rep. 2021 11 02; 37(5):109953.

View in: PubMed

authors with profiles

Tanmoy Mondal

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support